Chromium
An unproven-essential mineral with one falsified hype cycle and one unsettled glucose claim.
C-
Evidence grade
C
Worth it
$5-10/month
Typical cost
DoseTrials and products use 200 to 1,000 mcg/day, most commonly as chromium picolinate, with polynicotinate and chloride forms also sold; no form has proven superior in outcomes. Dietary intake runs about 25 to 35 mcg/day. Nothing about the dose literature is anchored to a demonstrated deficiency or requirement.
BasisChromium's career is a case study: a mineral of unproven essentiality, one hype cycle (body composition) thoroughly falsified, and one live claim (glucose) sustained by meta-analyses of trials too weak to settle it.
Chromium is a trace element sold, usually as chromium picolinate, for blood sugar control, cravings, and body composition. We grade Chromium C- on evidence and C for worth-it at about $5-10 per month.
What it does
Chromium is a trace element sold, usually as chromium picolinate, for blood sugar control, cravings, and body composition. Its proposed role is in insulin signaling. It has been a supplement staple since the 1990s, which is itself most of its story.
What the research says
Small HbA1c reductions in diabetes meta-analyses built from low-quality trials
Evidence: weak. Poolings of chromium trials in type 2 diabetes find HbA1c reductions on the order of 0.3 to 0.6 percentage points, with high heterogeneity and short, small, bias-prone underlying trials; effects in people without diabetes are absent. Even taken at face value, the pooled effect belongs to the category of adjunct noise unless better trials appear.
The body-composition fame failed replication
Evidence: moderate. Chromium picolinate's 1990s muscle-and-fat claims came from two small flawed studies. Subsequent controlled trials and meta-analysis (including a Cochrane-era pooling) found effects on weight and body composition at or near zero (a pooled weight difference of about a kilogram at the most generous reading, from low-quality trials). This is one of the supplement industry's best-documented hype cycles.
Its essentiality is itself unsettled science
Evidence: emerging. No clear chromium deficiency syndrome has ever been demonstrated in humans, and EFSA concluded in 2014 that chromium's essentiality is not substantiated and set no requirement. The 'essential trace mineral' framing on labels is a legacy position regulators are quietly abandoning.
Chromium's career is a case study: a mineral of unproven essentiality, one hype cycle (body composition) thoroughly falsified, and one live claim (glucose) sustained by meta-analyses of trials too weak to settle it. Something may be there for diabetic glucose control; the literature as built cannot say how much, and the honest grade for 'possibly a small effect, unreliably measured' is C-.
Is it worth it?
Evidence (C-) sits below the leaderboard floor, so the worth-it grade is capped at C+ however inexpensive it is; the derived value lands at C. About $7 a month at common doses. Derived from the October 2026 worth-it model.
Typical cost
$5-10/month
Common form, not a brand recommendation
Dosage context established
Trials and products use 200 to 1,000 mcg/day, most commonly as chromium picolinate, with polynicotinate and chloride forms also sold; no form has proven superior in outcomes. Dietary intake runs about 25 to 35 mcg/day. Nothing about the dose literature is anchored to a demonstrated deficiency or requirement.
Worth-it leaderboard
Chromium sits outside the worth-it top 20.
Chromium sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
At usual doses (up to about 400 mcg/day) chromium is well tolerated. High-dose picolinate has rare case reports of kidney and liver injury and rhabdomyolysis, causality uncertain. It can add to glucose-lowering medication effects, the standard caution for this category, and may reduce levothyroxine absorption if taken together, so separate them. In vitro chromosome-damage findings for the picolinate form at extreme exposures have not translated into a demonstrated human risk at label doses, and the record states that balance rather than either extreme.
Longevity Lab Report
Chromium news. Graded when it happens.
The grade on this page stays free. The email carries the news on chromium: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the diabetes meta-analyses, the body-composition replication record, and EFSA's essentiality assessment. Chromium's entry in the queue rested on source-list frequency; its evidence file is graded here on its own terms.
- 2026-10-23|Not listed under any goal: the graded findings (low-quality glucose data, null body composition) do not map onto the library's ten goals.
The week's longevity and biohacking news.
This grade for Chromium rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.